Skip to main content

Fried food 'fine for heart' if cooked with olive oil

Eating fried food may not be bad for the heart, as long as you use olive or sunflower oil to make it, experts say.
They found no heightened risk of heart disease or premature death linked to food that had been cooked in this way.
But the investigators stress that their findings, from studying the typical Spanish diet in which these "healthy" oils are found in abundance, do not apply to lard or other cooking oils.
So traditional fry ups should not be the order of the day, bmj.com reports.
When food is fried it becomes more calorific because the food absorbs the fat of the oils.
And experts know that eating lots of fat-laden food can raise blood pressure and cause high cholesterol, which are risk factors for heart disease.
For the study, the researchers at the Autonomous University of Madrid surveyed 40,757 adults about their diet.
The participants were asked about what types of food they ate in a typical week and how that food was prepared and cooked.
None of the adults had any sign of heart disease at the start of the 11-year study, but by the end of it 606 heart disease events and 1,134 deaths had occurred.
When the researchers looked at these heart events in detail, they could find no link with fried food in the diet.
This, they believe, is down to the type of oil the food is cooked in.


The Med diet
In an accompanying editorial, Professor Michael Leitzmann from the University of Regensburg in Germany said: "Taken together, the myth that frying food is generally bad for the heart is not supported by available evidence.
"However, this does not mean that frequent meals of fish and chips will have no health consequences.
"The study suggests that specific aspects of frying food are relevant, such as the oil used, together with other aspects of the diet."
Mediterranean diets have long been hailed as healthy, being packed full of low-fat, high-fibre fresh fruits and vegetables, as well as fresh fish.
And numerous studies have shown a balanced diet such as this can cut the risk of illnesses like cancer and heart disease.
Victoria Taylor, a senior heart health dietitian at the British Heart Foundation, said: "Before we all reach for the frying pan, it's important to remember that this was a study of a Mediterranean diet rather than British fish and chips. Our diet in the UK will differ from Spain, so we cannot say that this result would be the same for us too.
"Participants in this study used unsaturated fats such as olive and sunflower oil to fry their food. We currently recommend swapping saturated fats like butter, lard or palm oil for unsaturated fats as a way of keeping your cholesterol down and this study gives further cause to make that switch.
"Regardless of the cooking methods used, consuming foods with high fat content means a high calorie intake. This can lead to weight gain and obesity, which is a risk factor for heart disease. A well-balanced diet, with plenty of fruit and veg and only a small amount of high fat foods, is best for a healthy heart."

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n